Vimarsana
Biggest News Aggregation in the World

Page 9 - Project Bioshield News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Project Bioshield. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Project Bioshield Today - Breaking & Trending Today

Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma - Vimarsana News

Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Published: May 11, 2023

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

Source: prnewswire.com
Related Topics:
United StatesChristopherj SchaberUs CongressUs DevelopmentWhile The CompanyDrug AdministrationDevelopment AuthorityEuropean Medicines AgencyNational Institute Of AllergyPrnewswire Soligenix IncSoligenix IncDefense Threat Reduction AgencyOur Public Health SolutionsExchange CommissionBiomedical Advanced ResearchOutcome Expected NextChief Executive OfficerAbout Cutaneoust Cell LymphomaPublic Health SolutionsNational InstituteInfectious DiseasesProject BioshieldPriority Review Voucher
Soligenix Announces Pricing of $8.5 Million Public Offering - Vimarsana News

Soligenix Announces Pricing of $8.5 Million Public Offering

Published: May 5, 2023

PRINCETON, N.J., May 5, 2023 /PRNewswire/ -- Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an... | May 5, 2023

Source: marketscreener.com
Related Topics:
New YorkUnited StatesUs CongressNational Institute Of AllergyBiomedical Advanced ResearchPrnewswire Soligenix IncDefense Threat Reduction AgencyUs DevelopmentDevelopment AuthorityOur Public Health SolutionsSoligenix IncA Gp Alliance Global PartnersExchange CommissionAlliance Global PartnersPublic Health SolutionsNational InstituteInfectious DiseasesProject BioshieldPriority Review VoucherNc Stock ExchangePress ReleaseS Sngx Us8342235053
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma - Vimarsana News

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Published: May 4, 2023

Results Confirm and Extend Response Results from Phase 3 FLASH Study PRINCETON, N.J., May 4, 2023 /PRNewswire/ -- Soligenix, Inc. , a late-stage biopharmaceutical company focused on developing and... | May 4, 2023

Source: marketscreener.com
Related Topics:
Brian PoligoneChristopherj SchaberDrug AdministrationExchange CommissionDevelopment AuthorityPrnewswire Soligenix IncUs CongressDefense Threat Reduction AgencyEuropean Medicines AgencyWhile The CompanyBiomedical Advanced ResearchUs DevelopmentSoligenix IncNational Institute Of AllergyOur Public Health SolutionsRochester Skin Lymphoma Medical GroupResults ConfirmExtend Response ResultsDaavlin SeriesComposite AssessmentIndex Lesion SeverityRochester Skin Lymphoma MedicalPrincipal InvestigatorLeading Enrolling InvestigatorChief Executive Officer
Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors - Vimarsana News

Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors

Published: May 3, 2023

/PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

Source: prnewswire.com
Related Topics:
Christopherj SchaberOffice Of Orphan Products DevelopmentBiomedical Advanced ResearchOur Public Health SolutionsNational Institutes Of HealthDevelopment AuthorityDrug AdministrationSyracuse UniversityHarvard School Of Public HealthUs DevelopmentWhile The CompanyUs CongressHoward University College Of MedicineCenters For Disease ControlDefense Threat Reduction AgencyOrphans CoteExchange CommissionPublic HealthNational Institute Of AllergySoligenix IncNational InstitutesDisease ControlOrphan Products DevelopmentDrug ActCote Orphan
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease - Vimarsana News

Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet's Disease

Published: May 1, 2023

Phase 2/3-Ready Orphan Disease Program Complements Company's Existing Late-Stage Rare Disease Pipeline PRINCETON, N.J., May 1, 2023 /PRNewswire/ -- Soligenix, Inc. , a late-stage... | May 1, 2023

Source: marketscreener.com
Related Topics:
United StatesChristopherj SchaberDefense Threat Reduction AgencyDrug AdministrationUs DevelopmentUs CongressExchange CommissionBiomedical Advanced ResearchWhile The CompanyNational Institute Of AllergyDevelopment AuthorityOur Public Health SolutionsSoligenix IncReady Orphan Disease Program Complements CompanyExisting Late Stage Rare DiseaseSilk Road TherapeuticsChief Executive OfficerOrphan DrugFast TrackMiddle EastEast AsiaPublic Health SolutionsNational InstituteInfectious DiseasesProject Bioshield